The future of the global oncology molecular diagnostic market looks promising with opportunities in the hospital and diagnostic center, reference laboratory, pharmaceutical and biotechnology, and academic & research institute markets. The global oncology molecular diagnostic market is expected to reach an estimated $7.3 billion by 2030 with a CAGR of 13.2% from 2024 to 2030. The major drivers for this market are augmenting incidence of different cancer related cases, increasing demand for rapid and accurate diagnosis, and growing number of blood donation campaigns.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the oncology molecular
diagnostic market by product type (instruments, reagents, and others), type
(blood cancer, breast cancer, prostate cancer, colorectal cancer, liver cancer,
lung cancer, skin cancer, cervical cancer, and others), technology (polymerase
chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid
amplification technology (INNAT), chips & microarrays, sequencing, mass
spectroscopy, transcription mediated amplification (TMA), and others), end use
(hospitals and diagnostic centers, reference laboratories, pharmaceutical and
biotechnology, academic & research institutes, and others), and region
(North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will
grow at a faster pace and why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the business
risks and competitive threats in this market?
Q.6. What are the
emerging trends in this market and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, blood,
breast, prostate, colorectal, liver, lung, skin, and cervical are the major
segments of oncology molecular diagnostic market by type. Lucintel forecasts
that breast is expected to witness highest growth over the forecast period due
to increasing awareness of breast cancer and women's health and rising demand
for minimally invasive and accurate diagnostic tests.
Within this market,
hospital and diagnostic center is expected to witness highest growth over the
forecast period due to the extensive use of molecular diagnostic tests in this
field by medical proffesionals.
North America is
expected to witness highest growth over the forecast period due to rising
prevalence of cancer among population, existence of favorable reimbursement for
health, and presence of key players in the region.
Abbott, Becton,
Dickinson, F. Hoffmann-La Roche, Cepheid, Bayer, Agilent Technologies, Danaher,
Hologic, and Sysmex are the major suppliers in the oncology molecular
diagnostic market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment